Serotonin-2 receptors and human sleep: effect of a selective antagonist on EEG power spectra.
To investigate the effect on the sleep EEG, a 1-mg oral dose of SR 46349B, a novel 5-HT2 antagonist, was administered three hours before bedtime. The drug enhanced slow wave sleep (SWS) and reduced stage 2 without affecting subjective sleep quality. In nonREM sleep (NREMS) EEG slow-wave activity (SWA; power within 0.75-4.5 Hz) was increased and spindle frequency activity (SFA; power within 12.25-15 Hz) was decreased. The relative NREMS power spectrum showed a bimodal pattern with the main peak at 1.5 Hz and a secondary peak at 6 Hz. A regional analysis based on bipolar derivations along the antero-posterior axis revealed significant 'treatment' x 'derivation' interactions within the 9-16 Hz range. In enhancing SWA and attenuating SFA, the 5-HT2 receptor antagonist mimicked the effect of sleep deprivation, whereas the pattern of the NREMS spectrum differed.
Landolt
H P
HP
Institute of Pharmacology, University of Zürich, Switzerland.
Meier
V
V
Burgess
H J
HJ
Finelli
L A
LA
Cattelin
F
F
Achermann
P
P
Borbély
A A
AA
D000328:Adult; D001831:Body Temperature / Q000187:drug effects / Q000502:physiology; D004569:Electroencephalography / Q000187:drug effects*; D005464:Fluorobenzenes / Q000494:pharmacology*; D006339:Heart Rate / Q000187:drug effects / Q000502:physiology; D006801:Humans; D008297:Male; D010636:Phenols / Q000494:pharmacology*; D011985:Receptors, Serotonin / Q000187:drug effects* / Q000502:physiology; D012702:Serotonin Antagonists / Q000494:pharmacology*; D012890:Sleep / Q000187:drug effects* / Q000502:physiology; D012894:Sleep Stages / Q000187:drug effects* / Q000502:physiology
D005464:Fluorobenzenes; D010636:Phenols; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; C076033:SR 46349B